Abstract
During evolution, multicellular organisms have developed an impressive arsenal of defense and repair mechanisms to counteract threats such as infection and trauma. Such an inflammatory response begins with the detection of the potential life-threatening event by recognizing so-called danger signals. These signal molecules have been classically divided into: i) Exogenous, pathogen-associated molecular patterns (PAMPs) [1], which are conserved motifs on pathogens that are not found in higher eukaryocytes; and ii) endogenous innate danger molecules, also named damage-associated molecular patterns (DAMPs) or alarmins, which are structurally diverse proteins rapidly released by the host itself during infection or (sterile) tissue damage [2].
Chapter PDF
References
Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20: 197–216
Bianchi ME (2007) DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 81: 1–5
Harris HE, Raucci A (2006) Alarmin(g) News about danger: Workshop on innate danger signals and HMGB1. EMBO Rep 7: 774–778
Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191–195
Liu Y, Chen GY, Zheng P (2009) CD24-Siglec G/10 discriminates danger-from pathogen-associated molecular patterns. Trends Immunol 30: 557–561
Liu R, Mori S, Wake H, et al (2009) Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin’s effect on binding. Acta Med Okayama 63: 203–211
Bierhaus A, Stern DM, Nawroth PP (2006) RAGE in inflammation: a new therapeutic Target? Curr Opin Investig Drugs 7: 985–991
Chavakis T, Bierhaus A, Al Fakhri N, et al (2003) The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198: 1507–1515
Liliensiek B, Weigand MA, Bierhaus A, et al (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 113: 1641–1650
Goova MT, Li J, Kislinger T, et al (2001) Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 159: 513–525
Cataldegirmen G, Zeng S, Feirt N, et al (2005) RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 201: 473–484
Park L, Raman KG, Lee KJ, et al (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4: 1025–1031
Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949–955
Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331–342
Ueno H, Matsuda T, Hashimoto S, et al (2004) Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170: 1310–1316
Wang H, Bloom O, Zhang M, et al (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251
van Zoelen MA, Laterre PF, van Veen SQ, et al (2007) Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 35: 2799–2804
Yang H, Ochani M, Li J, et al (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 101: 296–301
Qin S, Wang H, Yuan R, et al (2006) Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 203: 1637–1642
Suda K, Kitagawa Y, Ozawa S, et al (2006) Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 30: 1755–1762
Wang H, Liao H, Ochani M, et al (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10: 1216–1221
Hotchkiss RS, Nicholson DW (2006) Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6: 813–822
Hotchkiss RS, Chang KC, Swanson PE, et al (2000) Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 1: 496–501
Tian J, Avalos AM, Mao SY, et al (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 8: 487–496
Yang H, Hreggvidsdottir HS, Palmblad K, et al (2010) A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 107: 11942–11947
Wittkowski H, Sturrock A, van Zoelen MA, et al (2007) Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 35: 1369–1375
Orlova VV, Choi EY, Xie C, et al (2007) A novel pathway of HMGBl-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 26: 1129–1139
Frommhold D, Kamphues A, Hepper I, et al (2010) RAGE and ICAM-1 Cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood 116: 841–849
Uchida T, Shirasawa M, Ware LB, et al (2006) Receptor for advanced glycation end-products is a marker of type i cell injury in acute lung injury. Am J Respir Crit Care Med 173: 1008–1015
Cheng C, Tsuneyama K, Kominami R, et al (2005) Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 18: 1385–1396
Englert JM, Hanford LE, Kaminski N, et al (2008) A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 172: 583–591
Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M (2006) The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 19: 1437–1445
Buckley ST and Ehrhardt C (2010) The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010:917108
Queisser MA, Kouri FM, Konigshoff M, et al (2008) Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am J Respir Cell Mol Biol 39: 337–345
Demling N, Ehrhardt C, Kasper M, Laue M, Knels L, Rieber EP (2006) Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res 323: 475–488
Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Muller M (1998) Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol (Noisy-le-grand) 44: 1147–1157
He M, Kubo H, Ishizawa K, et al (2007) The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol 293:L1427–L1436
Reynolds PR, Schmitt RE, Kasteler SD, et al (2010) Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am J Respir Cell Mol Biol 42: 545–551
van Zoelen MA, Schouten M, de Vos AF, et al (2009) The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 182: 4349–4356
van Zoelen MA, van der Sluijs KF, Achouiti A, et al (2009) Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 391: 265–273
Lutterloh EC, Opal SM, Pittman DD, et al (2007) Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 11:R122
van Zoelen MA, Schmidt AM, Florquin S, et al (2009) Receptor for advanced glycation end products facilitates host defense during Escherichia coli-induced abdominal sepsis in mice. J Infect Dis 200: 765–773
van Zoelen MA, Achouiti A, Schmidt AM, et al (2010) Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during escherichia coli peritonitis. Crit Care Med 38: 1414–1422
van Zoelen MA, Yang H, Florquin S, et al (2009) Role of Toll-Like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 31: 280–284
Park JS, Svetkauskaite D, He Q, et al (2004) Involvement of Toll-Like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370–7377
Payen D, Lukaszewicz AC, Belikova I, et al (2008) Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 34: 1371–1376
Foell D, Wittkowski H, Vogl T, Roth J (2007) S100 Proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 81: 28–37
Cole AM, Kim YH, Tahk S, et al (2001) Calcitermin, a novel antimicrobial peptide isolated from human airway secretions. FEBS Lett 504: 5–10
Bopp C, Hofer S, Weitz J, et al (2008) SRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 147: 79–83
Hudson BI, Harja E, Moser B, Schmidt AM (2005) Soluble levels of receptor for advanced glycation endproducts (SRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 25: 879–882
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media LLC
About this chapter
Cite this chapter
van Zoelen, M.A.D., Achouiti, A., van der Poll, T. (2011). The Role of Receptor for Advanced Glycation Endproducts (RAGE) in Infection. In: Vincent, JL. (eds) Annual Update in Intensive Care and Emergency Medicine 2011. Annual Update in Intensive Care and Emergency Medicine 2011, vol 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18081-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-18081-1_1
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-18080-4
Online ISBN: 978-3-642-18081-1
eBook Packages: MedicineMedicine (R0)